Life science product company Bio-Rad Laboratories has launched the PTC Harmony Thermal Cycler line. The line is designed to ...

Bio-Rad Laboratories (NYSE:BIO) shares fell 9.5% to $253.48 on Thursday after the life sciences company cut its 2026 revenue forecast and reported first-quarter results that missed analyst ...

Thank you, Regina. My name is Ruben Argueta, Bio-Rad's new Head of IR. Today, we will review the financial results for the first quarter ended March 31, 2026, and provide an update on key business ...

Bio-Rad Laboratories lowered its 2026 revenue growth outlook to between -3% and +0.5% due to Middle East disruptions, while Amgen raised its full-year revenue and EPS guidance on strong product ...

Bio-Rad Laboratories reduced its 2026 currency-neutral revenue growth guidance to between -3% and +0.5%, citing significant disruption from the Middle East conflict that has dented its Diagnostics ...

Q1 2026 earnings call recap: guidance cut on Middle East headwinds, ddPCR/QX700 momentum, margins & FCF outlook—read key takeaways.

Bio-Rad Laboratories (NYSE:BIO) reported first-quarter 2026 results that fell within its revenue guidance range, while ...

Rad's first quarter 2026 results showed resilience, with the company reporting revenue within its guidance. The region has ...

Bio-Rad Laboratories Inc. (BIO) on Thursday reported a first-quarter loss of $527.1 million, after reporting a profit in the same period a ...

RareLabs, a division of AlphaRose Therapeutics, named Rob Freishtat, MD as CEO. Charles Hirner joined NuvemRx as SVP of ...

Bio-Rad Laboratories, Inc., a global leader in life science research and clinical diagnostics products, today announced the ...

The Saudi Arabia in vitro diagnostics (IVD) market is set for steady growth, driven by the increasing prevalence of chronic ...